ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT
For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozol...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-09-01
|
| Series: | Опухоли женской репродуктивной системы |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/335 |
| _version_ | 1826557301748662272 |
|---|---|
| author | J.F.R. Robertson S.E. Come S.E. Jones L. Beex M. Kaufmann A. Makris J.W.R. Nortier K. Possinger L.-E. Rutqvist |
| author_facet | J.F.R. Robertson S.E. Come S.E. Jones L. Beex M. Kaufmann A. Makris J.W.R. Nortier K. Possinger L.-E. Rutqvist |
| author_sort | J.F.R. Robertson |
| collection | DOAJ |
| description | For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozole is also more effective as an adjuvant treatment in early, operable breast cancer and is being increasingly used in the adjuvant setting. Generally, the selective oestrogen receptor modulators (SERMs), such as toremifene, droloxifene, idoxifene, ralox- ifene, and arzoxifene, show minimal activity in tamoxifen-resistant disease and show no superiority over tamoxifen as first-line treatments. In addition to these agents, other treatment options for advanced disease include high-dose oestrogens and progestins. Response rates for high- dose oestrogens and tamoxifen are similar, but the use of oestrogens is limited by their toxicity profile. Consequently, there is a need for new endocrine treatment options for breast cancer, particularly for use in disease that is resistant to tamoxifen or AIs. Fulvestrant (_Faslodex_) is a new type of steroidal oestrogen receptor (ER) antagonist that downregulates cellular levels of the ER and progesterone receptor and has no agonist activity. This paper reviews the key efficacy and tolerability data for fulvestrant in postmenopausal women in the context of other endocrine therapies and explores the potential role of fulvestrant within the sequencing of endocrine therapies for advanced breast cancer. |
| first_indexed | 2024-04-10T01:56:56Z |
| format | Article |
| id | doaj.art-d725b19995d34eca907003a2bf7065a4 |
| institution | Directory Open Access Journal |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| last_indexed | 2025-03-14T08:26:26Z |
| publishDate | 2014-09-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj.art-d725b19995d34eca907003a2bf7065a42025-03-02T13:05:31ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272014-09-0101334010.17650/1994-4098-2008-0-1-33-40351ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANTJ.F.R. Robertson0S.E. Come1S.E. Jones2L. Beex3M. Kaufmann4A. Makris5J.W.R. Nortier6K. Possinger7L.-E. Rutqvist8Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenUnit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, SwedenFor many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozole is also more effective as an adjuvant treatment in early, operable breast cancer and is being increasingly used in the adjuvant setting. Generally, the selective oestrogen receptor modulators (SERMs), such as toremifene, droloxifene, idoxifene, ralox- ifene, and arzoxifene, show minimal activity in tamoxifen-resistant disease and show no superiority over tamoxifen as first-line treatments. In addition to these agents, other treatment options for advanced disease include high-dose oestrogens and progestins. Response rates for high- dose oestrogens and tamoxifen are similar, but the use of oestrogens is limited by their toxicity profile. Consequently, there is a need for new endocrine treatment options for breast cancer, particularly for use in disease that is resistant to tamoxifen or AIs. Fulvestrant (_Faslodex_) is a new type of steroidal oestrogen receptor (ER) antagonist that downregulates cellular levels of the ER and progesterone receptor and has no agonist activity. This paper reviews the key efficacy and tolerability data for fulvestrant in postmenopausal women in the context of other endocrine therapies and explores the potential role of fulvestrant within the sequencing of endocrine therapies for advanced breast cancer.https://ojrs.abvpress.ru/ojrs/article/view/335 |
| spellingShingle | J.F.R. Robertson S.E. Come S.E. Jones L. Beex M. Kaufmann A. Makris J.W.R. Nortier K. Possinger L.-E. Rutqvist ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT Опухоли женской репродуктивной системы |
| title | ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT |
| title_full | ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT |
| title_fullStr | ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT |
| title_full_unstemmed | ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT |
| title_short | ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT |
| title_sort | endocrine treatment options for advanced breast cancer the role of fulvestrant |
| url | https://ojrs.abvpress.ru/ojrs/article/view/335 |
| work_keys_str_mv | AT jfrrobertson endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT secome endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT sejones endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT lbeex endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT mkaufmann endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT amakris endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT jwrnortier endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT kpossinger endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant AT lerutqvist endocrinetreatmentoptionsforadvancedbreastcancertheroleoffulvestrant |